Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)

Funding Opportunity PAR-22-140 from the NIH Guide for Grants and Contracts. The STRIPE program seeks to support pre-clinical research projects utilizing state-of-the-art cancer biology methods and model systems that study how radiopharmaceutical therapy (RPT) agents affect the biology of normal tissue, tumor cells and the tumor microenvironment. Ideally, proposed aims will be designed to test hypotheses on how RPT dynamically impacts cancer biology processes, which can serve as the pre-clinical basis for developing new targeting strategies and approaches. Studies supported by this PAR will ultimately inform the rationale and design of new RPT-based clinical trials.